FH and cardiovascular disorder: Specifically, children with a genetic diagnosis of FH should start pharmacological treatment when LDL-C levels are > 3.5 mmol/L, while for children with premature cardiovascular disease, or the presence of a family member with high cholesterol levels but without confirmed FH mutation, therapy should be started when LDL-C concentrations are > 4.0 mmol/L [4].